DBV Technologies (DBVT) climbed ~41% in the premarket on Wednesday after the French biotech announced that a Phase 3 trial ...
Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...
Investor's Business Daily on MSN
DBV launches, up as much as 46%, on a new approach to peanut allergy
Shares of DBV Technologies launched Wednesday after the company reported promising results for its peanut allergy treatment.
The 1995 discovery of regulatory T cells underpins newer investigations pointing to potential allergy treatments and ...
DBV Technologies SA said its experimental skin patch helped young children with a peanut allergy in a crucial study.
Fruit, tree nuts, and legumes most commonly cause an allergy, while insects, meat, and herbs and spices least commonly cause ...
If you’ve been sneezing nonstop or waking up with watery eyes and a stuffy nose, it may not be a winter cold. North Texas has entered the early stages of cedar fever season, that time of year when ...
Mast cell platform can expand to carry other payloads, such as molecules, viruses, proteins and drug-loaded nanoparticles.
Mammalian meat allergy (MMA) is one of the few known food allergies caused by an environmental trigger—a tick bite. In simple ...
Managing alpha-gal syndrome can be hard for anyone, but for farmers who are in close contact with mammals — the allergy can ...
Mast cell platform can expand to carry other payloads, such as molecules, viruses, proteins and drug-loaded nanoparticles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results